课题基金 / 基金详情

Human Leukemia Growth Inhibition by a Novel Retinoid

Human Leukemia Growth Inhibition by a Novel Retinoid
新型类维生素A抑制人类白血病生长
批准号:
7409181
负责人:
JOSEPH A FONTANA
金额:
$46.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2012-04-30
关键词:
3-chlorophenol4-bromophenolA549AHPNAcidsAcridine OrangeAcridinesActinsAcuteAcute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAcute Promyelocytic LeukemiaAcute leukemiaAdoptedAdriamycin PFSAdult Acute Lymphocytic LeukemiaAdverse effectsAffectAffinityAgarAgeAge-YearsAgonistAldehydesAlkaline PhosphataseAlkylationAlkynesAmericanAminesAnalysis of VarianceAnimalsAntibodiesAntigensAntineoplastic AgentsAntsAnusApoptosisApoptosis PromoterApoptosis RegulatorApoptoticAppendixAra-CAssesAutoradiographyAzidesB-LymphocytesBCL1 OncogeneBacteriaBaltimoreBedsBexaroteneBindingBinding SitesBiohazardous SubstanceBiologicalBiological AssayBiological MarkersBiopsyBiteBlast CellBlast PhaseBlood CirculationBody WeightBody Weight decreasedBone MarrowBone Marrow TransplantationBoranesBoronic AcidsBreastBreast CarcinomaBritishBromidesBuffersCD3 AntigensCD34 geneCDKN1A geneCanadaCarbon DioxideCarboxy-LyasesCarboxylic AcidsCell CycleCell Cycle ArrestCell DeathCell LineCell NucleusCellsCessation of lifeChemistryChemotherapy-Oncologic ProcedureChimeric ProteinsChloride IonChloridesChromosomes, Human, Pair 9ChronicChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaClassClassificationClinicClinicalCodon NucleotidesCollaborationsColorCompetitive BindingComplement component C1sComplement component C4aCompomersConditionConsensusConsensus SequenceCountCouplingCp CAPCritical PathwaysCytarabineCytogeneticsCytolysisCytoplasmCytosineD CellsDNADactinomycinDataDatabasesDaunorubicinDetectionDevelopmentDiagnosisDialysis procedureDiseaseDisease ProgressionDisease remissionDisease-Free SurvivalDissociationDockingDominant-Negative MutationDoseDown-RegulationDoxorubicinDrug vehicleE2F1 geneEatingEelsElectronsElementsEmbryoEngraftmentEnvironmentEnzyme-Linked Immunosorbent AssayEpidermisEpitopesEquilibriumEthersEthyl EtherEtiologyEtoposideEventExperimental DesignsExposure toEyeFCGR3B geneFailureFamilyFamily memberFelis catusFemaleFibroblastsFicollFigs - dietaryFlow CytometryFoodFrequenciesFrightFutureGasesGelGenbankGene ExpressionGene Expression RegulationGene TargetingGenerationsGenesGenetic TranscriptionGenomicsGroupingGrowthGrowth FactorGuidelinesHL-60 CellsHamstersHarvestHelix (Snails)HematopoieticHepatocyteHeterogeneous-Nuclear RibonucleoproteinsHourHumanHuman GenomeHydrogenationHypaqueImatinib mesylateImmunophenotypingImplantIn VitroIn complete remissionInbred C3H MiceIncubatedIndividualIndolesInduction of ApoptosisInhibitory Concentration 50Injection of therapeutic agentInvestigationIodidesIonsIsomerismIsopropyl ThiogalactosideKaryotypeKetonesKnock-outLNCaPLabelLaboratoriesLasersLateralLearningLegal patentLettersLeukemic CellLifeLigand Binding DomainLigandsLightLiteratureLocationLongevityLuciferasesLyeLymphoblastic LeukemiaMAPK14 geneMCF7 cellMagnetic Resonance ImagingMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of lungMann-Whitney U TestManuscriptsMapsMarrowMaximum Tolerated DoseMeasuresMediatingMediator of activation proteinMembraneMessenger RNAMethodologyMethodsMinorMinorityModalityModelingModificationMolecularMolecular ConformationMorphologyMountain LionMusMutateMutationMyelogenousMyeloid LeukemiaN-formylpiperidineNF-kappa BNFKB Activation PathwayNail plateNamesNaphthaleneNaphthalenesNational Cancer InstituteNeckNeuro-Oncological Ventral Antigen 2Non obeseNuclearNuclear ReceptorsNude MiceNumbersObject AttachmentOncogenesOrgan Culture TechniquesPCNA genePTPRC genePathologyPathway interactionsPatientsPeptidesPharmaceutical PreparationsPhasePhase III Clinical TrialsPhenolsPhenotypePhosphotransferasesPhysical DialysisPhysiologic pulsePlasmidsPlayPolymerase Chain ReactionPongidaePopulationPositioning AttributePost-Translational RegulationPrincipal InvestigatorProceduresProcessProductionPrognostic MarkerProliferatingProstateProteasome InhibitorProtein OverexpressionProtein Tyrosine KinaseProteinsProteolysisProtocols documentationProtonsPtosisPublicationsPulse takingPurposeQuantitative Structure-Activity RelationshipRHOA geneRXRRadioRangeRateRattusReactionReactive Oxygen SpeciesRefluxRefractoryRegulationRelapseRelative (related person)ReporterReportingRepressionResearchResearch InstituteResearch PersonnelResistanceRetinoid ReceptorRetinoidsRetroviral VectorRetroviridaeReverse Transcriptase Polymerase Chain ReactionRoleRouteRunningSCID MiceSM 22 muscle proteinSamplingScheduleSchemeScoreSecondary toSerineSerumShockSignal PathwaySignal TransductionSinusSiteSodiumSodium AzideSodium ChlorideSourceSpecimenSpleenStandards of Weights and MeasuresStem cellsSterilityStimulusStructureStructure of thyroid parafollicular cellSurfaceSurface AntigensSystemT-LymphocyteTMEDATNFRSF10A geneTNFRSF10B geneTNFRSF5 geneTailTarsTeaTechniquesTestingTheftTherapeuticTherapeutic AgentsTherapeutic IndexTimeTopoisomeraseTopoisomerase IITorsionToxic effectToxicologyTracheaTrainingTranscriptional ActivationTransgenic MiceTranslationsTransplantationTreatment EfficacyTreatment ProtocolsTretinoinTumor BankTumor Necrosis Factor-alphaTumor Necrosis FactorsTumor PromotersTyrosine Kinase InhibitorUnited States National Institutes of HealthUniversitiesUntranslated RegionsUp-RegulationUpper armVeinsVertebral columnVertebratesViralVitamin AWeekWeight GainWestern BlottingWithdrawalWorkalanine aminopeptidaseanalogbacterial lysatebasebeta Globinboronic acidc-myc Genescancer cellcell growthcell growth regulationcell killingcell typechemotherapeutic agentchemotherapychlorinationcomputer studiesconformerdaydesigndetectordiabeticdimerdosagedrug efficacyear helixelectron donorexperienceexpression vectorfallsfootfusion genegel electrophoresisgenetic regulatory proteinhelenalinhnRNP A1human TNF proteinhuman stem cellsimprovedin vivoin vivo Modelindexingindoleinhibitor/antagonistirradiationkeratinizationkillingsleukemiamalignant breast neoplasmmelanomamembermessenger ribonucleoproteinmethyl groupmolecular dynamicsmouse modelmulticatalytic endopeptidase complexmutantn-butyllithiumnext generationnitrenenovelolder patientoncologyoncoprotein p21outcome forecastoxazolidinep65peripheral bloodpharmacophorepol genespre-clinicalpreventprogramspromoterprotein Kprotein functionreceptorreceptor bindingresearch studyresponsescaffoldsizesodium sulfidestannanestemtitanium carbidetranscription factortumorvector

项目摘要

项目成果

JOSEPH A FONTANA的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN/CD437) belongs to a class of adamantyl retinoids (AR) that induce apoptosis through as yet undefined mechanism(s). We have now identified an AHPN analog 4-[3-(1-adamanyly)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-CI-AHPC), which binds to, but does not activate, the retinoic acid nuclear receptors. 3-C1-AHPC displays decreased toxicity compared to AHPN but continues to display high efficacy in inhibiting human acute myelogenous leukemia (AML) cell growth in vitro and mouse AML cells in vivo. In addition, we have found that 3-C1-AHPC induces the expression of a novel protein termed CARP-1. We recently identified CARP-1 as an important regulator of apoptosis by the ARs. Hypothesis: In this proposal we hypothesize that 3-C1-AHPC and newly synthesized analogs are highly active in inhibiting the growth of human primary AML cells in NOD-SCID mice and thus represent potential therapeutic agents in the treatment of AML. In addition, we also hypothesize that 3-CL-AHPC/analog apoptosis signaling is through its activation of the important transcriptional regulator, NFkB, and CARP-l-mediated pathways. Our hypothesis is based on the following observations. 1) 3-CI-AHPC inhibits the growth of AML cells in a syngeneic mouse model, patient derived AML cells, and human AML cell lines. 2) Inhibition of NFkB activation or inhibition of CARP-1 expression blocks 3-C1-AHPC-mediated apoptosis. We will confirm our hypothesis by conducting the following specific aims. Aim 1: Synthesize new analogs of 3-C1-AHPC. Aim 2: Demonstrate that 3-C1-AHPC and its analogs inhibit in vivo growth of human primary AML cells in NOD-SCID mice and display reduced toxicity. Aim 3: Delineate the mechanism(s) by which 3-CI-AHPC enhances CARP-1 expression and CARP-l-dependent reduced topoisomerase lIa levels. Aim 4: Delineate the pathway by which 3-C1-AHPC activates NFkB and its role in apoptosis induction.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1158/1535-7163.mct-10-0546
发表时间: 2010-11
期刊: Molecular cancer therapeutics
影响因子: 5.7
作者: [Farhana L, Dawson MI, Xia Z, Aboukameel A, Xu L, Liu G, Das JK, Hatfield J, Levi E, Mohammad R, Fontana JA]
通讯作者: Fontana JA
Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.
孤儿核受体小异二聚体伴侣配体和凋亡诱导剂 (E)-4-[3-(1-金刚烷基)-4-羟基苯基]-3-氯肉桂酸的杂原子取代类似物。
DOI: 10.1021/jm200051z
发表时间: 2011
期刊: Journal of medicinal chemistry
影响因子: 7.3
作者: [Xia,Zebin, Farhana,Lulu, Correa,RicardoG, Das,JayantaK, Castro,DavidJ, Yu,Jinghua, Oshima,RobertG, Reed,JohnC, Fontana,JosephA, Dawson,MarciaI]
通讯作者: Dawson,MarciaI
DOI: 10.1038/cdd.2010.84
发表时间: 2011-01
期刊: Cell death and differentiation
影响因子: 12.4
作者: []
通讯作者:
Human Leukemia Growth Inhibition by a Novel Retinoid
  • 批准号:
    7087066
  • 项目类别:
  • 资助金额:
    $45.85万
  • 财政年份:
    2004
  • 负责人:
    JOSEPH A FONTANA
  • 依托单位:
Human Leukemia Growth Inhibition by a Novel Retinoid
  • 批准号:
    7237940
  • 项目类别:
  • 资助金额:
    $45.86万
  • 财政年份:
    2004
  • 负责人:
    JOSEPH A FONTANA
  • 依托单位:
Human Leukemia Growth Inhibition by a Novel Retinoid
  • 批准号:
    6815356
  • 项目类别:
  • 资助金额:
    $47.22万
  • 财政年份:
    2004
  • 负责人:
    JOSEPH A FONTANA
  • 依托单位:
Human Leukemia Growth Inhibition by a Novel Retinoid
  • 批准号:
    6914222
  • 项目类别:
  • 资助金额:
    $45.59万
  • 财政年份:
    2004
  • 负责人:
    JOSEPH A FONTANA
  • 依托单位: